ライフサイエンスコーパス: pentostatin

1 ts (25%) had toxicity requiring them to stop pentostatin.

2 (MMF), denileukin diftitox (denileukin), or pentostatin.

3 steroid taper was begun after three doses of pentostatin.

4 ine, 3 underwent splenectomy, and 1 received pentostatin.

5 ntial for inappropriate immunosuppression by pentostatin.

6 r were decreased in septic mice treated with pentostatin.

7 ly improved at 48 hours in mice treated with pentostatin.

8 ly attenuated in septic animals treated with pentostatin (0.42 +/- 0.05 versus 0.21 +/- 0.04; p < 0.0

9 re treated with six cycles of induction with pentostatin (2 mg/m(2) on day 1), cyclophosphamide (600

10 emia (CLL), we initiated a trial of combined pentostatin (2 mg/m2), cyclophosphamide (600 mg/m2), and

11 Pentostatin (2'-deoxycoformycin), an inhibitor of adenos

12 etanercept 26%, MMF 60%, denileukin 53%, and pentostatin 38%.

13 Pentostatin 4 mg/m(2) with cyclophosphamide 600 mg/m(2)

14 All patients received pentostatin 4 mg/m(2).

15 Patients received pentostatin 4 mg/m2 intravenously every 2 weeks for 12 d

16 Patients received pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rit

17 either bendamustine (90 mg/m2 days 1, 2) or pentostatin (4 mg/m2 days 1, 15).

18 x with the adenosine analogs pentostatin and pentostatin-5'-monophosphate.

19 etanercept 48%, MMF 44%, denileukin 62%, and pentostatin 57%.

20 e agent (5) or combined with: rituximab (2), pentostatin (6), fludarabine, cyclophosphamide, and ritu

21 10(-13) M) (8R)-hydroxyl-2'-deoxycoformycin (pentostatin), a transition state analogue, and (6S)-hydr

22 Pentostatin, a potent inhibitor of adenosine deaminase,

23 Pentostatin, a potent inhibitor of adenosine deaminase,

24 ic inhibition of AMP-metabolizing pathway by Pentostatin activates muscle AMPK, confers resistance to

25 nt 24 hrs in advance of the inciting insult, pentostatin also has the unique potential for use as a t

26 potential usefulness of 2'-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a

27 Pentostatin, an adenosine deaminase inhibitor, leads to

28 Eight dogs were conditioned with 6x4 mg/m pentostatin and 100 cGy TBI, whereas two dogs received 3

29 t introduction of purine nucleoside analogs (pentostatin and cladribine) changed the natural history

30 The purine analogs, pentostatin and cladribine, induce high remission rates

31 We previously reported that pentostatin and cyclophosphamide (PC) is active and well

32 work has shown that SS1P in combination with pentostatin and cyclophosphamide can result in durable t

33 , sirolimus, mycofenolate mofetil, imatinib, pentostatin and infusion of mesenchymal stem cells have

34 rm and in complex with the adenosine analogs pentostatin and pentostatin-5'-monophosphate.

35 nt of adenosine deaminase in the presence of pentostatin and revealed a protein thermal network that

36 l curves for patients initially treated with pentostatin and those crossed over were similar.

37 splenectomy, interferon alfa-2a and alfa-2b, pentostatin, and cladribine.

38 Of the purine analogs active in CLL, pentostatin appears to be the least myelosuppressive.

39 Coformycin and pentostatin are structurally related N-nucleoside inhibi

40 a randomized, intergroup study who received pentostatin as an initial treatment or who crossed over

41 Two hundred forty-one patients treated with pentostatin as initial therapy (n = 154) or who crossed

42 t-binding inhibitor/transition state analog (pentostatin) at single and multiple temperatures.

43 We hypothesized that addition of pentostatin before transplantation could, in part, subst

44 ally, we discuss the differential impacts of pentostatin binding on overall protein flexibility versu

45 Pentostatin, cyclophosphamide, and rituximab (PCR) in CL

46 of these results, we are currently studying pentostatin, cyclophosphamide, and rituximab (PCR) thera

47 Thus, this novel regimen of pentostatin, cyclophosphamide, and rituximab for previou

48 f a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients

49 to groups to receive saline, bortezomib, the pentostatin/cyclophosphamide (PC) regimen, or the bortez

50 Pentostatin, denileukin diftitox, mycophenolate mofetil,

51 Patients were randomly assigned to pentostatin doses of 0, 0.5, 1.0, 1.5, and 2.0 mg/m(2) w

52 Pentostatin doses of 1.0 and 1.5 mg/m(2) had the highest

53 In rats given pentostatin either 2 hrs after the insult, or 24 hrs bef

54 lant Consortium performed a phase 2 trial of pentostatin for steroid-refractory chronic GVHD in 51 ch

55 Of the 86 courses of pentostatin given, 39 were administered at doses of 5.0

56 Pentostatin has activity in patients with steroid-refrac

57 Pentostatin has activity in refractory chronic GVHD in c

58 Pentostatin has immunosuppressive effects that are curre

59 The nucleoside analogue, pentostatin, has demonstrated high complete response rat

60 We examined the toxicity and efficacy of pentostatin in a prospective phase II trial in corticost

61 Building on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we in

62 Herpes zoster was seen within 1 year after pentostatin in five patients (19%).

63 Pentostatin increased the likelihood of success as defin

64 n the presence of both 1-deaza-adenosine and pentostatin, indicating similar impacts of either ligand

65 Many treatments exist, including cladribine, pentostatin, interferon-alpha, splenectomy, rituximab (m

66 neal cecal slurry) were treated with 1 mg/kg pentostatin intraperitoneally 24 hrs before, or intraven

67 Pentostatin is a highly effective regimen for hairy cell

68 Pentostatin is an active agent in heavily pretreated T-c

69 The combination of alemtuzumab and pentostatin is feasible and effective in T-cell neoplasm

70 Of the purine analogs active in CLL, pentostatin may be least myelosuppressive.

71 therapy with intravenous alemtuzumab and/or pentostatin, median progression-free survival and overal

72 with a variety of agents, including 30 with pentostatin; none achieved complete remission (CR).

73 cGy TBI, whereas two dogs received 3x4 mg/m pentostatin plus 100 cGy TBI.

74 though the nucleoside analogs cladribine and pentostatin produce high response rates in patients with

75 he kinetics of lymphodepletion and safety of pentostatin (PT) conditioning in alloNST.

76 e results of therapy with new agents such as pentostatin, pulse cyclophosphamide, long-wavelength ult

77 e nucleoside purine analogues cladribine and pentostatin results in lengthy remissions in nearly all

78 a and variant (HCL/HCLv) was to determine if pentostatin-rituximab (DCFR) and bendamustine-rituximab

79 Treatment of septic mice with pentostatin significantly decreased leukocyte rolling an

80 Pharmacokinetic studies showed pentostatin significantly inhibited adenosine deaminase

81 onor lymphocyte infusion (DLI) alone or with pentostatin to convert to complete donor chimerism.

82 We hypothesized that addition of pentostatin to GVHD prophylaxis with tacrolimus and mini

83 These data indicate that the novel use of pentostatin to prevent systemic inflammatory response sy

84 tients with a confirmed complete response to pentostatin treatment, 5- and 10-year relapse-free survi

85 es to the septic challenge were abrogated by pentostatin treatment.

86 ignancies do not appear to be increased with pentostatin treatment.

87 Pentostatin was administered to 28 patients who had rela

88 me were abrogated and survival improved when pentostatin was not given until after signs of the illne

89 We hypothesized that combining pentostatin with cyclophosphamide would have less myelot